Submission deadline: Thursday 12th June 2025 (23:59 CEST).

Abstract Submission Terms & Conditions

The Euretina Session on ‘Results of Clinical Trials and Late Breaking News’ will be a showcase for the latest innovative and breakthrough research topics available before the Congress begins on 4 September 2025.

Terms & Conditions

– The ‘Results of Clinical Trials and Late Breaking News’ abstract submission portal opens Friday, 2nd May 2025 and will be closing Thursday, 12th June 2025 (23:59 CEST).

– Please note that you must be a EURETINA Member in order to submit an abstract. If you are not a member please CLICK HERE to join.

– Presenting authors must be ophthalmologists or researchers.

– Co-authors must be ophthalmologists, researchers or other healthcare professionals who have contributed to the project.

– Each applicant may submit a maximum of 2 abstracts.

– If you choose to submit an abstract(s) we will use your personal details to keep you updated on its status including whether it has been accepted for presentation at the Euretina Congress.

– If your abstract(s) is accepted for presentation, your contact details (name and email address) will be sent to a third-party Audio Visual Company in order for them to contact you in relation to uploading your presentation.

Review & Evaluation

– Abstracts focussing on the first presentation of results of a major clinical trial are encouraged for submission.

– All submitted abstracts will be reviewed before a final selection is made.

– Specific topics that need to be covered in the Congress programme will be considered before making the final selection of accepted abstracts. The decision of the Euretina Review Committee is final.

– If your abstract is accepted for oral presentation in the Euretina Session, you will be informed of this by email in August 2025.

– It is not possible to reschedule the assigned time of an accepted abstract.

– If your abstract is not accepted for oral presentation, you may be offered the opportunity to present it as an e-poster.

Abstract Submission

– All submitted abstracts must be in English and follow the structured format below:

• Title (250 characters max / average )
• Purpose (100 words max)
• Setting/Venue (50 words max)
• Methods (200 words max)
• Results (200 words max)
• Conclusions (200 words max)

– All submitted abstracts MUST be submitted in the presenting author’s name.

– Financial Disclosure: Please indicate Yes/No with details where applicable. Indicate whether the presenting author or any co-author has a financial interest in the subject matter or receives funds from any mentioned companies.

Further Instructions

– Presentation titles must not include company names.

– Accepted presentations must not include company branded slides.

– Formulae should, in general, be avoided.

– When using abbreviations or acronyms for the first time, care should be taken to spell them out in full with the abbreviation in parentheses after the full word(s) the first time it appears in the text. The abbreviation should be used alone thereafter.

– There is an embargo on oral presentations until the first day of the annual Congress programme.

– Euretina does not take any ownership of the copyright of a presentation. However, presenters are required to sign a Non-Exclusive Transfer of Rights document at the time of the presentation upload.

– Accepted presentations will be displayed on Euretina On Demand after the Congress.

For any queries, please contact [email protected].

Closing Date: Thursday, 12th June 2025, 23:59 CEST.

Abstract acceptance notification: You will be contacted about the acceptance status of your abstract in August 2025.